A PA denial is not the end of the process. Experienced specialty pharmacy operations teams know this, but the practical reality is that many denials go uncontested — not because they're incontestable, but because the appeals process is time-consuming, the outcome is uncertain, and the immediate operational pressure of the next 40 submissions in the queue makes it easier to move on than to fight.
The cost of that calculus is real. Published data on PA appeal outcomes consistently shows that a meaningful percentage of initial denials — estimates vary but often range from 30–60% for commercially insured patients with medically appropriate prescriptions — are reversed on appeal when a complete and well-constructed appeal is filed. The denials that don't get appealed include many that would have been overturned. Those reversals represent medications that patients didn't receive, revenue the pharmacy didn't capture, and prescriber relationships that take a hit when the pharmacy reports a denial without offering a path to reversal.
Step 1: Triage the Denial — Is It Appealable?
Not every denial warrants an appeal. The first step in an effective appeals workflow is identifying which denials are worth contesting, because the time and documentation required for a well-constructed appeal is not trivial.
Denials worth appealing:
- Step therapy denials where the prescriber believes step therapy is clinically inappropriate — these are among the most frequently reversed on appeal with prescriber attestation
- Off-label use denials where the use is supported by NCCN guidelines or major peer-reviewed compendia — payers frequently approve on appeal when compelling clinical evidence is submitted
- Formulary non-preferred denials where the preferred alternative is clinically contraindicated for this patient — formulary exceptions are common and often granted with prescriber attestation
- Administrative denials (incorrect coding, missing fields) — these are typically correctable through resubmission rather than formal appeal, and should be addressed as resubmissions with the administrative error corrected
- Quantity limit denials where the prescribed quantity reflects clinical standards — quantity limit exceptions are routinely granted when the clinical rationale is documented
Denials less likely to warrant formal appeal:
- Coverage denials for drugs that are explicitly non-covered under the patient's plan benefit design (excluded drug categories)
- Denials based on the patient's plan specifically excluding the prescribed drug class from benefit coverage
- Denials where the payer has already completed a peer-to-peer review and maintained denial after physician review
We're not saying don't appeal a denial if you've already been through P2P review — external appeals have a different standard than internal appeals, and cases that failed P2P review have been overturned at the independent review level. We're saying that calibrating effort to likelihood of success is the operational reality of a high-volume appeals workflow.
Peer-to-Peer Review: The Most Direct Appeal Path
Peer-to-peer (P2P) review is a mechanism most commercial payers offer that allows the prescribing physician to speak directly with the payer's reviewing physician to discuss the clinical rationale for the denied medication. It's available for initial coverage decisions at many payers and requires an explicit request — it doesn't happen automatically after a denial.
The P2P process typically works like this:
- Denial received; specialty pharmacy or prescriber's office contacts payer to request P2P review
- Payer arranges a call between the prescribing physician and the payer's medical reviewer (typically within 24–72 hours of request)
- Prescribing physician presents clinical rationale on the call
- Payer reviewer makes a determination, typically within 24–48 hours after the call
P2P review has several practical characteristics worth knowing. First, it requires physician time — the prescriber needs to make themselves available for the call, which means the prescriber's office needs to know the P2P request has been filed and be prepared to participate. The pharmacy's role in facilitating this is to notify the prescriber's office immediately when a P2P-eligible denial comes back, with the payer's contact information and the deadline for requesting the call.
Second, P2P outcomes are not simply about having a good conversation. The reviewing physician has criteria they're applying. Understanding those criteria — typically available in the payer's prior authorization guidelines — and ensuring the prescribing physician is prepared to address them directly makes the P2P call more effective. A prescriber who knows the payer is looking for documentation of step therapy failure will come prepared with that documentation; one who hasn't been briefed may spend the call presenting general clinical rationale that doesn't address the specific denial basis.
Building the Formal Appeal: Documentation Requirements
When P2P review isn't available, isn't successful, or when an administrative appeal is the appropriate path, the formal appeal submission typically requires:
- Appeal request letter — A formal letter identifying the patient, the denied drug, the denial reference number, and the specific grounds for appeal. The letter should cite the applicable plan appeal procedures and any relevant state law provisions if applicable.
- Prescriber letter of medical necessity — The treating physician's letter documenting why this specific drug is medically necessary for this patient, addressing the payer's denial rationale directly. Generic medical necessity letters are less effective than letters that specifically address the criteria the payer cited in the denial.
- Clinical documentation — Relevant clinical records supporting the medical necessity claim: diagnosis documentation, prior treatment history demonstrating step therapy failure (where applicable), laboratory results, imaging, pathology reports, or other supporting evidence the prescriber's clinical decision is based on.
- Clinical literature — For off-label use appeals or cases where the prescribed agent is supported by NCCN guidelines or peer-reviewed evidence, including the relevant citations strengthens the clinical basis of the appeal.
The quality of the appeal package is the primary determinant of appeal success. Appeals that directly address the specific denial rationale, include complete clinical documentation, and cite applicable clinical guidelines perform substantially better than generic appeal requests that don't engage with the payer's stated basis for denial.
Appeal Timelines and Filing Deadlines
Appeals are subject to filing deadlines that vary by payer and plan type. Most commercial plans require that internal appeals be filed within 60–180 days of the denial notice. Medicaid managed care organization appeals are typically subject to state-regulated timelines — often 30–90 days from the denial determination, depending on state. Missing a filing deadline can result in the loss of appeal rights for that denial determination.
For specialty pharmacy operations teams, tracking appeal deadlines for outstanding denials is an operational requirement. A denial that was received two months ago and hasn't been triaged for appeal may be approaching or past the deadline. Building appeal deadline tracking into the PA management workflow — rather than relying on staff to remember filing windows — is how pharmacies ensure that appealable denials don't expire uncontested.
External Review: The Next Level
When internal appeals are denied, most commercial plan members in fully insured plans have the right to request external review by an Independent Review Organization (IRO). Under the ACA and state insurance regulations, IRO decisions are binding on the plan for standard coverage disputes. The external review process is separate from the internal appeal process and involves a different — and genuinely independent — clinical review.
External review is particularly valuable for cases involving experimental or investigational treatment determinations, non-formulary exception denials where the internal appeal process was not successful, and urgent or emergency care denials. The external reviewer applies clinical standards independent of the payer's internal criteria, which creates opportunities to overturn denials that the payer's internal process consistently maintains.
Most specialty pharmacy operations teams don't pursue external review as frequently as internal appeals — the process is longer, the documentation requirements are higher, and the cases that reach that level are typically the most complex. But for patients on high-cost specialty medications where the clinical justification is strong, external review is a legitimate and available path that the pharmacy can help prescribers and patients navigate.
